GB2410744A - Indol derivatives and their use as kinase inhibitors - Google Patents

Indol derivatives and their use as kinase inhibitors Download PDF

Info

Publication number
GB2410744A
GB2410744A GB0511267A GB0511267A GB2410744A GB 2410744 A GB2410744 A GB 2410744A GB 0511267 A GB0511267 A GB 0511267A GB 0511267 A GB0511267 A GB 0511267A GB 2410744 A GB2410744 A GB 2410744A
Authority
GB
United Kingdom
Prior art keywords
kinase inhibitors
indol derivatives
indol
derivatives
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0511267A
Other versions
GB0511267D0 (en
GB2410744B (en
Inventor
Steven W Andrews
Michael E Garst
Xialing Guo
Jonathan J Hebert
Thomas Malone
Julie A Wurster
Iii Clarence Eugene Hull
Yuan-Xing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,097 external-priority patent/US6699863B1/en
Priority claimed from US10/389,416 external-priority patent/US6747025B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of GB0511267D0 publication Critical patent/GB0511267D0/en
Publication of GB2410744A publication Critical patent/GB2410744A/en
Application granted granted Critical
Publication of GB2410744B publication Critical patent/GB2410744B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Description

GB 2410744 A continuation (72) cont Xialing Guo Jonathan J Hebert Thomas
Malone Julie A Wurster Clarence Eugene Hull lil Yuan-Xing Guo (74) Agent and/or Address for Service: Hoffmann Eitle Sardinia House, Sardinia Street,
52 Lincoln's Inn Fields, LONDON,
WC2A 3LZ, United Kingdom
GB0511267A 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease Expired - Fee Related GB2410744B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30697502A 2002-11-27 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease
PCT/US2003/036988 WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Publications (3)

Publication Number Publication Date
GB0511267D0 GB0511267D0 (en) 2005-07-13
GB2410744A true GB2410744A (en) 2005-08-10
GB2410744B GB2410744B (en) 2006-04-12

Family

ID=32475339

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511267A Expired - Fee Related GB2410744B (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease

Country Status (7)

Country Link
AU (1) AU2003295658A1 (en)
BR (1) BR0316744A (en)
CA (1) CA2507780A1 (en)
DE (1) DE10393799T5 (en)
ES (1) ES2292329B2 (en)
GB (1) GB2410744B (en)
WO (1) WO2004050621A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012907A (en) * 2005-04-28 2008-03-14 Boehringer Ingelheim Int Novel compounds for treating inflammatory diseases.
US8338415B2 (en) 2006-01-24 2012-12-25 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CN104211632B (en) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2 indolone derivatives with tyrosine-kinase enzyme inhibition activity and preparation method and application
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Enzyme Inhibition and Medicinal Chemistry Vol. 18, No. 3, 2003, pages 243-252 *

Also Published As

Publication number Publication date
BR0316744A (en) 2005-10-18
WO2004050621A3 (en) 2004-07-15
DE10393799T5 (en) 2005-10-13
CA2507780A1 (en) 2004-06-17
WO2004050621A2 (en) 2004-06-17
ES2292329A1 (en) 2008-03-01
AU2003295658A1 (en) 2004-06-23
GB0511267D0 (en) 2005-07-13
GB2410744B (en) 2006-04-12
ES2292329B2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
GB2420897A (en) Universal display exposure monitor using personal locator service
GB2408609A (en) Modular financial service instrument
GB2393823A (en) Electronic trading system
GB2407009A (en) Portal for distributing business and product information
GB2405642A (en) Methods of regulating differentiation in stem cells
YU95203A (en) Peptides and related molecules that bind to tall-1
MX9606401A (en) Indolinone compounds for the treatment of disease.
GB2392756A (en) Systems and methods for providing a futures contracts on options contracts exchange device
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
GB2397919A (en) Systems and methods for quoting a two-sided market
TR200101747T2 (en) 4- and 5-alkynyl oxindoles and 4- and 5-alkenyloxindoles.
ATE250602T1 (en) PYRIMIDO(6,1-A)ISOCHINOLINONE DERIVATIVES
AU5307300A (en) A composition and method for cleaning surfaces
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
MXPA05010174A (en) Sustituted indoline and indole derivatives.
GB2410744A (en) Indol derivatives and their use as kinase inhibitors
GB2423083A (en) Azole-based kinase inhibitors
GB2412372A (en) Pyrazine-based tubulin inhibitors
DE60320784D1 (en) STANDS FOR MODULATING BONE GROWTH
WO2008090417A3 (en) Inhibition of nf-kb
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors
GB2470336A (en) Using a hash value as a pointer to an application class in a communications device
EP0987250A4 (en) Indole dicarboxylic acid derivatives
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
MXPA05011783A (en) Peptides having an ace inhibiting effect.

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20081119